Eurofins Scientific patented a method to predict cancer immunotherapy responsiveness by analyzing T cell receptor diversity in CD8+ T cell subsets. By isolating and determining TCR diversity values, subjects likely to respond to immune checkpoint inhibitors can be identified and treated effectively. GlobalData’s report on Eurofins Scientific gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Eurofins Scientific SE - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Eurofins Scientific, Telomerase reverse transcriptase screening was a key innovation area identified from patents. Eurofins Scientific's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

Predicting cancer immunotherapy response based on tcr diversity

Source: United States Patent and Trademark Office (USPTO). Credit: Eurofins Scientific SE

A recently granted patent (Publication Number: US11858994B2) outlines a method for treating cancer in individuals who are likely to respond to immunotherapy with an immune checkpoint inhibitor. The method involves isolating CD8+PD-1+ cells from a peripheral blood sample, determining the T cell receptor (TCR) diversity value of the isolated cells, and comparing it to a reference value to identify potential responders. If the sample TCR diversity value is higher than the reference value, the subject is deemed likely to respond to the treatment, and the immune checkpoint inhibitor is administered to treat the cancer effectively.

The patent further details the calculation of the sample TCR diversity index through TCR repertoire analysis and the selection of reference values from non-responders to the immunotherapy. Various TCR diversity indices such as Shannon index, Simpson index, and DE50 index are utilized in the method to determine the likelihood of response to the immune checkpoint inhibitor. Additionally, the patent specifies the use of specific immune checkpoint inhibitors like PD-1 inhibitors, nivolumab, and pembrolizumab in the treatment process. By employing a personalized approach based on TCR diversity analysis, this method aims to enhance the efficacy of immunotherapy in cancer treatment by targeting individuals who are more likely to benefit from the treatment.

To know more about GlobalData’s detailed insights on Eurofins Scientific, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies